Vericel to Host First-Quarter 2016 Earnings Webcast and Conference Call on May 10, 2016
April 27, 2016 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Vericel to Present at 15th Annual Needham Healthcare Conference
April 08, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases...
Results from Vericel’s Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented Today at ACC and Published in The Lancet
April 04, 2016 11:45 ET
|
Vericel Corporation
CAMBRIDGE, Mass., April 04, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions
March 29, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 29, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy
March 28, 2016 08:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 28, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Reports Fourth-Quarter and Year-End 2015 Financial Results
March 14, 2016 07:45 ET
|
Vericel Corporation
Total Revenues of $15.4 Million Reported for the Fourth Quarter Conference Call Today at 8:00am Eastern Time CAMBRIDGE, Mass., March 14, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation...
Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy
March 10, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 10, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Enters Into $10 Million Credit Facility and $5 Million Term Loan Agreement With Silicon Valley Bank
March 09, 2016 08:00 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 09, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel to Present at 28th Annual ROTH Conference
March 08, 2016 16:30 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 08, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (Nasdaq:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...
Vericel Announces FDA Acceptance for Filing of BLA for MACI for the Treatment of Symptomatic Cartilage Defects in the Knee
March 07, 2016 09:15 ET
|
Vericel Corporation
CAMBRIDGE, Mass., March 07, 2016 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and...